Cataracts

·MeSH: Cataract

Prevalence

1359.5 / 100K

4 drugs in development·3 companies·2 clinical trials

Drug Pipeline by Phase

Phase 2(3)

Drug	Company
0.4% zoc2017217	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
0.4% zoc2017217	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
0.4% ZOC2017217	Crinetics Pharmaceuticals, Inc. (CRNX)

Phase 4(1)

Drug	Company
Control	Crinetics Pharmaceuticals, Inc. (CRNX)

BioSniper tracks 4 drugs in development for Cataracts across 3 companies.

There are 2 clinical trials targeting Cataracts tracked by BioSniper.

The estimated prevalence of Cataracts is approximately 1359.5 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.